Introduction {#s1}
============

Extended-spectrum β-lactamases (ESBLs) can hydrolyze penicillins and oxyimino-cephalosporins, such as ceftazidime (CAZ), cefotaxime (CTX), and ceftriaxone, which have reportedly played important roles in the treatment of infections caused by *Enterobacteriaceae*, including *Escherichia coli* \[[@R01]\]. Recently, the prevalence of ESBL-producing *E. coli* (ESBL-EC) has been dramatically increasing worldwide \[[@R02]-[@R04]\]. In Japan, CTX-M-type ESBL-EC, which exhibits co-resistance to fluoroquinolones, has been detected more frequently than TEM- or SHV-type ESBL-EC \[[@R05], [@R06]\]. Infections caused by ESBL-EC are reportedly associated with poor clinical outcomes, inappropriate empirical antibiotic therapy, longer hospital stays, and greater hospital expenses \[[@R07]-[@R9]\].

Antimicrobial resistance patterns are often available for monitoring the endemicity of specific clones. In small- and medium-sized hospitals, antimicrobial resistance patterns are particularly useful for empiric therapy because it is difficult to routinely conduct genotyping in clinical laboratories. However, only few studies have been reported on trends and antimicrobial resistance patterns of ESBL-EC in limited regions. Because of the increasing clinical importance of ESBL-EC, we should carefully monitor the prevalence and antimicrobial resistance profile of ESBL-EC at our facility. Thus, the aim of this study was to investigate the trends of the rate of detection and antimicrobial resistance of ESBL-EC at our hospital.

Methods {#s2}
=======

Setting {#s2a}
-------

Fukuoka University Chikushi Hospital is a 310-bed university-affiliated hospital located in the southwestern district of Japan. This study was approved by the Fukuoka University Medical Ethics Review Board (R18-014). This study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.

Collection and identification of isolates {#s2b}
-----------------------------------------

*E. coli* clinical isolates were recovered from inpatients and outpatients who visited Fukuoka University Chikushi Hospital between January 2012 and December 2017. Only one isolate per patient per year was included in this study. For those patients from whom more than one isolate was recovered, only the first isolate for which the results of antimicrobial susceptibility testing were available was included. The isolates were identified using the automated Vitek-2 system (Sysmex bioMerieux, Tokyo, Japan).

Antimicrobial susceptibility testing {#s2c}
------------------------------------

Antimicrobial susceptibility testing was performed using the automated Vitek-2 system, following the manufacturer's instructions. The breakpoint (susceptible, intermediate, or resistant) was determined according to the M100-S27 performance standards established by the Clinical and Laboratory Standards Institute (CLSI) \[[@R10]\]. Nine antimicrobial agents were used for susceptibility testing: cefmetazole (CMZ), flomoxef (FMOX), imipenem (IPM), meropenem (MEPM), amikacin (AMK), gentamicin (GM), minocycline (MINO), ciprofloxacin (CPFX), and levofloxacin (LVFX).

ESBL detection {#s2d}
--------------

ESBL detection was performed by the double disk diffusion using both CTX, CAZ, and cefpodoxime (CPDX) alone and in combination with clavulanic acid. An increase in zone size of greater than or equal to 5 mm for CTX, CAZ, and CPDX with and without clavulanic acid was taken as an indication of ESBL production.

Statistical analysis {#s2e}
--------------------

Categorical variables were compared using the Chi-squared test or Fisher's exact test, as appropriate. Temporal trends of antimicrobial resistance were evaluated using linear regression analysis. The JMP software program (version 10, SAS Institute Inc., Cary, NC, USA) was used for all the statistical analyses. P \< 0.05 was considered statistically significant.

Results {#s3}
=======

Prevalence of ESBL-EC {#s3a}
---------------------

A total of 2,146 *E. coli* clinical isolates were recovered between January 2012 and December 2017. Of those, 1,303 (60.7%) isolates were included in this study ([Fig. 1](#F1){ref-type="fig"}). Further, 983 (75.4%) of the included 1,303 were non-ESBL-EC and 320 (24.6%) were ESBL-EC. The proportion of ESBL-EC among all the *E. coli* isolates was relatively stable throughout the study period (22.6-27.2%) ([Fig. 2](#F2){ref-type="fig"}).

![Samples analyzed in the present study.](jocmr-11-635-g001){#F1}

![Yearly rate of detection of ESBL-EC among all the *E. coli* isolates.](jocmr-11-635-g002){#F2}

Antimicrobial resistance profile of non-ESBL-EC and ESBL-EC {#s3b}
-----------------------------------------------------------

Almost all the *E. coli* isolates were susceptible to CMZ, FMOX, IPM, MEPM, and AMK, and there was no difference between non-ESBL-EC and ESBL-EC in the rate of resistance to these antibiotics. However, the rate of resistance to GM, MINO, CPFX, and LVFX was significantly higher in ESBL-EC than in non-ESBL-EC (17.5% vs. 10.0%, 19.1% vs. 7.7%, 87.5% vs. 24.2%, and 87.5% vs. 23.5%, respectively; P \< 0.01) ([Fig. 3](#F3){ref-type="fig"}). In ESBL-EC, the rate of resistance to GM and MINO was stable throughout the study period, whereas that to CPFX and LVFX increased over the study period (P = 0.048 and P = 0.062, respectively) ([Fig. 4](#F4){ref-type="fig"}).

![Antimicrobial resistance profiles of non-ESBL-EC and ESBL-EC (\*\*P \< 0.01).](jocmr-11-635-g003){#F3}

![Trends in the rates of resistance of ESBL-EC for GM, MINO, CPFX, and LVFX (\*P \< 0.05).](jocmr-11-635-g004){#F4}

Change in the antimicrobial resistance pattern of ESBL-EC {#s3c}
---------------------------------------------------------

A total of 34 resistance patterns were identified based on the resistance profile of the nine antibiotics in the *E. coli* isolates (pattern IDs: Null, I-a-f, II-a-h, III-a-i, IV-a-f, V-a-c, and VII) ([Table 1](#T1){ref-type="table"}). Of the 983 non-ESBL-EC isolates, the pattern ID Null (susceptible to all nine antibiotics) was the predominant resistance pattern (68.2%), followed by ID II-h (resistance to CPFX and LVFX), ID III-h (resistance to GM, CPFX, and LVFX), and ID I-e (resistance to MINO). Of the 320 ESBL-EC isolates, ID II-h (resistance to CPFX and LVFX) was the predominant resistance pattern (57.2%), followed by ID III-i (resistance to MINO, CPFX, and LVFX), ID III-h (resistance to GM, CPFX, and LVFX), and ID Null (susceptible to all antibiotics).

###### Antimicrobial Resistance Pattern of Non-Extended-Spectrum β-Lactamase-Producing *Escherichia coli* and Extended-Spectrum β-Lactamase-Producing *Escherichia coli*

  Number of antibiotics^a^   Pattern ID   Antibiotics   Non-ESBL (n = 983)   ESBL (n = 320)                                                             
  -------------------------- ------------ ------------- -------------------- ---------------- ------ ----- ---- ------ ------ ------ ----- ------ ----- ------
  0                          Null                                                                                                    670   68.2   24    7.5
  Subtotal                                                                                                                           670   68.2   24    7.5
  1                          I-a          CMZ                                                                                        5     0.5    0     0.0
                             I-b                                                              MEPM                                   1     0.1    0     0.0
                             I-c                                                                     AMK                             1     0.1    0     0.0
                             I-d                                                                           GM                        22    2.2    11    3.4
                             I-e                                                                                MINO                 34    3.5    0     0.0
                             I-f                                                                                       CPFX          5     0.5    0     0.0
  Subtotal                                                                                                                           68    6.9    11    3.4
  2                          II-a         CMZ           FMOX                                                                         1     0.1    1     0.3
                             II-b         CMZ                                                              GM                        2     0.2    0     0.0
                             II-c         CMZ                                                                   MINO                 0     0.0    1     0.3
                             II-d                                                                          GM   MINO                 5     0.5    2     0.6
                             II-e                                                                          GM          CPFX          2     0.2    1     0.3
                             II-f                                                                               MINO   CPFX          2     0.2    0     0.0
                             II-g                                                                               MINO          LVFX   1     0.1    0     0.0
                             II-h                                                                                      CPFX   LVFX   131   13.3   183   57.2
  Subtotal                                                                                                                           144   14.6   188   58.8
  3                          III-a        CMZ           FMOX                                               GM                        1     0.1    0     0.0
                             III-b        CMZ           FMOX                                                                  LVFX   0     0.0    1     0.3
                             III-c        CMZ                                                                          CPFX   LVFX   3     0.3    1     0.3
                             III-d        FMOX                               IPM              MEPM                                   1     0.1    0     0.0
                             III-e                                           IPM                                       CPFX   LVFX   1     0.1    0     0.0
                             III-f                                                                   AMK               CPFX   LVFX   1     0.1    0     0.0
                             III-g                                                                         GM   MINO          LVFX   1     0.1    0     0.0
                             III-h                                                                         GM          CPFX   LVFX   55    5.6    35    10.9
                             III-i                                                                              MINO   CPFX   LVFX   23    2.3    47    14.7
  Subtotal                                                                                                                           86    8.7    85    26.6
  4                          IV-a         CMZ           FMOX                                                           CPFX   LVFX   1     0.1    0     0.0
                             IV-b         CMZ                                                              GM          CPFX   LVFX   2     0.2    1     0.3
                             IV-c         CMZ                                                                   MINO   CPFX   LVFX   1     0.1    2     0.6
                             IV-d                                            IPM                                MINO   CPFX   LVFX   1     0.1    0     0.0
                             IV-e                                                                    AMK        MINO   CPFX   LVFX   0     0.0    1     0.3
                             IV-f                                                                          GM   MINO   CPFX   LVFX   5     0.5    6     1.9
  Subtotal                                                                                                                           10    1.0    10    3.1
  5                          V-a          CMZ           FMOX                                               GM          CPFX   LVFX   2     0.2    0     0.0
                             V-b          CMZ           FMOX                                                    MINO   CPFX   LVFX   2     0.2    2     0.6
                             V-c          CMZ                                                              GM   MINO   CPFX   LVFX   1     0.1    0     0.0
  Subtotal                                                                                                                           5     0.5    2     0.6
  7                          VII          CMZ           FMOX                 IPM              MEPM         GM          CPFX   LVFX   0     0.0    1     0.3
  Subtotal                                                                                                                           0     0.0    1     0.3

AMK: amikacin; CMZ: cefmetazole; CPFX: ciprofloxacin; ESBL: extended-spectrum beta-lactamase; ESBL-EC: ESBL-producing *Escherichia coli*; FMOX: flomoxef; GM: gentamicin; IPM: imipenem; LVFX: levofloxacin; MEPM: meropenem; MINO: minocycline. ^a^The number of antibiotics to which *Escherichia coli* isolates were resistant.

The yearly rates of detection of these predominant patterns in non-ESBL-EC and ESBL-EC are shown in [Figure 5](#F5){ref-type="fig"}. There was no change in the rate of isolates with pattern ID in non-ESBL-EC. In ESBL-EC, the rate of isolates with ID Null (susceptible to all antibiotics) decreased significantly from 10.0% in 2012 to 3.8% in 2017 (P \< 0.01), and the rate of isolates with ID III-h (resistance to GM, CPFX, and LVFX) increased from 4.0% in 2012 to 20.5% in 2017 (P \< 0.01).

![Changes in the antimicrobial resistance patterns of non-ESBL-EC and ESBL-EC.](jocmr-11-635-g005){#F5}

Discussion {#s4}
==========

In this study, we examined the trends of the rate of detection and antimicrobial resistance of ESBL-EC. The rate of detection of ESBL-EC has been 24.6% in the recent 6 years, which is in line with that reported by previous studies conducted in Japan \[[@R11]-[@R13]\]. However, at our hospital, the rate of detection of ESBL-EC exceeded 20% in 2012, and this value was higher than that during the same period at other facilities \[[@R03], [@R11], [@R14], [@R15]\]. A study reported that of 135 Japanese travelers, 55 (40.7%) carried ESBL after returning to Japan and that the majority of these carriers were returning from eastern and central Asia \[[@R16]\]. The Fukuoka Prefecture receives many immigrants and travelers from Southeast Asian countries with high carrier rates of ESBL-producing bacteria, which may contribute to the higher rate of detection of ESBL-EC at our hospital.

The rate of resistance of ESBL-EC to fluoroquinolones, such as CPFX and LVFX, was significantly higher than that of non-ESBL-EC, and this is consistent with the findings of a recent study conducted in Japan \[[@R13]\]. The resistance of ESBL-EC to fluoroquinolones is closely related to the genotype. There are three ESBL types: CTX-M, TEM, and SHV \[[@R01]\]. The CTX-M type is classified into five major groups: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 \[[@R17]\]. CTX-M-9 has been the predominant group in Japan since 2000 \[[@R06], [@R18]\]. A previous report has suggested that 75% of the 24 strains in the CTX-M-14 and CTX-M-27 groups, which belong to the CTX-M-9 group, are resistant to LVFX \[[@R03]\]. In addition, a recently disseminated lineage of *E. coli* designated sequence type ST131 according to multilocus sequence typing (MLST) is associated with CTX-M-15, which belongs to the CTX-M-1 group, that is usually fluoroquinolone resistant \[[@R19]\], and this type of ESBL-EC has been reported in Japan \[[@R03], [@R06]\]. In the antimicrobial resistance pattern analysis of ESBL-EC conducted in this study, the ESBL-EC pattern ID III-h, which shows resistance to GM as well as fluoroquinolones, increased from 4.0% in 2012 to 20.5% in 2017. Ender et al reported the transmission of an ESBL-EC ST131 producing CTX-M-15 strain that is resistant to GM, trimethoprim-sulfamethoxazole, and fluoroquinolones between a father and his daughter \[[@R20]\]. It has been suggested that specific ESBL-EC clones, such as isolates with ST131, CTX-M-14, CTX-M-15, or CTX-M-27, are transmitted in our hospital or the area surrounding our hospital.

Particularly for urinary tract infections, fluoroquinolones are still recommended as the initial treatment. However, in the present study, approximately 90% of ESBL-EC and 25% of non-ESBL-EC were resistant to fluoroquinolones, and fluoroquinolones as the initial treatment should be used with caution. Particularly in cases wherein infection with ESBL-EC is suspected, initial treatment with non-fluoroquinolone drugs should be considered. In previous studies, the use of immunosuppressive drugs or corticosteroids, the use of quinolones prior to isolation, nursing home-associated infections, and antibiotic administration within the preceding 30 days were the independent predictors associated with ESBL-EC bacteremia \[[@R13], [@R21]\]. Carbapenems may be recommended as the initial treatment for infectious cases with these factors \[[@R22]\]. In the present study, the sensitivity of ESBL-EC and non-ESBL-EC to CMZ and FMOX was as high as that previously reported in Japan \[[@R13], [@R21]\]. According to a previous multicenter retrospective study conducted using a propensity score, CMZ and FMOX were not inferior to carbapenems in the empirical and definitive treatment of ESBL-EC bacteremia regarding the 30-day mortality rates and clinical success; hence, these cephems may be effective alternatives to carbapenems in the treatment of ESBL-EC bacteremia \[[@R23]\].

There are several limitations to this study. First, this study was conducted at a single center; hence, it is not clear if our results reflect the trend of ESBL-EC in Japan or in only the Fukuoka Prefecture. Second, we did not routinely conduct antimicrobial sensitivity tests for tazobactam/piperacillin (TAZ/PIPC) against *E. coli*. Because TAZ/PIPC, like carbapenems, is recommended for the empirical treatment of infections with suspected urosepsis, it is necessary to consider routine sensitivity testing at our hospital. Third, we have not stored the strain nor determined the ESBL type using polymerase chain reaction and the ESBL-EC strain type using MLST in the *E. coli* isolates. However, there were only few reports in Japan that compared the antimicrobial resistance profile between ESBL-EC and non-ESBL-EC, and there were no reports concerning the trends in the resistance patterns.

In conclusion, the rate of detection of ESBL-EC has been 24.6% in the recent 6 years. Almost all the *E. coli* isolates were susceptible to CMZ, FMOX, IPM, MEPM, and AMK; however, the rates of resistance to GM, MINO, CPFX, and LVFX were significantly higher in ESBL-EC than in non-ESBL-EC. In ESBL-EC, the rates of the isolates susceptible to all antibiotics decreased significantly during the study period, and the rates of the isolates resistant to GM, CPFX, and LVFX increased over the study period. ESBL-EC is an important resistant strain for infection control or infection treatment, and it is necessary to carefully monitor the trends in its resistance profile and genotype in the future.
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